

## Data Sharing Statement

<b>Article Info</b>	http://dx.doi.org/10.21037/apm-21-61	
<b>Item</b>	<b>Question</b>	<b>Authors' Response (place "-" if not applicable)</b>
1	Would you like to share data collected for your study to others?	Yes.
2	If not, would you like to share the reason for your decision?	-
3	What data in particular will be shared?	The Baseline characteristics, correlation data and HFS evaluation data will be shared.
4	Any other documents will be shared? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	Statistical analysis plan, informed consent form, and clinical study report will also be shared if requested.
5	When will data availability begin?	From the publication date.
6	When will data availability end?	One year.
7	To whom will you share the data?	Medical oncologists and colorectal surgeons who are interested in studies of capecitabine-associated HFS.
8	For what type of analysis or purpose?	For analysis to evaluate the safety of EVOSKIN® palm and sole moisturizing cream and comparison with other treatment.
9	How or where can the data/documents be obtained?	Emails could be sent to the address below to obtain the shared data: <a href="mailto:gzdlhy@sina.com">gzdlhy@sina.com</a>
10	Any other restrictions?	We may balance the potential benefits and risks for each request and then provide the data that could be shared.